Objective
Diagnostic tests are essential to provide a targeted treatment of infectious diseases and to contain the further spread of multidrug resistant pathogens. Current methods are based either on cultivation or on PCR and have significant limitations concerning the clinical requirements to characterise pathogens including their resistance mechanisms within 3 hours. In MARA, we will develop and combine three radically novel technologies that will lead to substantial breakthroughs in science, medicine and industry and, as proof-of principle, use them to create a DNA-based molecular toolkit characterising pathogens.
First, the detection of pathogen-associated antigens will be performed by Autonomous Detection Nucleic Acids (AUDENA) that are independent of any laboratory instruments and sophisticated processing. The realisation of the AUDENA concept will lead to an autonomous, stable, simple and very economic novel sensor class applicable for any water-soluble substances. The second revolutionary technology in MARA employs a novel approach in protein mimicry and creation of artificial enzymes, which represents a breakthrough in several disciplines, such as biotechnology, biomedical manufacturing and the energy sector. The third breakthrough in this project represents the development of a Molecular Robot (MORO) that can specifically identify target cells and destroy them. In MARA, the MORO will be used for the lysis of bacterial cells to release intracellular antibiotic resistance associated antigens, but the long-term vision anticipates an application as antibiotic replacement for infectious diseases and a therapeutic agent for cancer treatment, which would represent one of the most important breakthroughs in medicine in the recent years.
To meet the highly ambitious objectives pointed out in this proposal, MARA is driven by a complementary, multidisciplinary team of leading experts, with a young, high-profile scientist in the lead.
Fields of science
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- natural sciencesbiological sciencesgeneticsDNA
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1210 Wien
Austria
See on map
Participants (5)
79098 Freiburg
See on map
SW7 2AZ London
See on map
Participation ended
HR8 1RZ Ledbury Herefordshire
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
8000 Aarhus C
See on map
54-427 Wroclaw
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.